FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings

Why It Matters

The decision underscores regulatory scrutiny of safety signals and trial design, delaying a potential treatment for Cushing’s syndrome and impacting Corcept’s valuation and pipeline timeline.

Key Takeaways

• FDA rejected relacorilant citing hypertension data concerns
• GRACE trial met primary endpoint, but population was highly enriched
• GRADIENT trial failed to achieve primary endpoint
• Four probable liver‑injury cases linked to relacorilant
• Corcept shares dropped over 10% after FDA letter

Pulse Analysis

The FDA’s complete response letter to Corcept Therapeutics highlights how early‑stage regulatory feedback can derail a late‑stage drug program. By flagging inadequacies in the hypertension sub‑analysis and warning of "significant review issues," the agency forced the biotech to confront methodological gaps before a formal submission. This pre‑emptive scrutiny is increasingly common for niche endocrine therapies, where safety margins are narrow and patient populations are heterogeneous.

Clinically, relacorilant showed promise in the GRACE Phase III trial, achieving its primary blood‑pressure endpoint in a highly selected cohort. However, the FDA noted that such enrichment could overstate real‑world benefit, a concern amplified by the GRADIENT study’s failure to meet its primary outcome. Coupled with four probable cases of drug‑induced liver injury, the benefit‑risk profile remains uncertain, prompting the regulator to demand additional data and a robust liver‑injury mitigation strategy before reconsideration.

From a market perspective, the CRL sent Corcept’s shares tumbling more than 10%, reflecting investor anxiety over delayed revenue and increased development costs. The setback also reverberates across the glucocorticoid receptor antagonist space, signaling that even drugs with strong mechanistic rationale must deliver clear safety and efficacy signals across diverse patient groups. Going forward, Corcept will need to design broader, possibly multi‑regional trials that address hypertension management and hepatic safety, while communicating a transparent risk‑management plan to regain regulatory and investor confidence.